Comments
Loading...

VitaSpring Biomedical Analyst Ratings

VSBCOTCEM
Logo brought to you by Benzinga Data

VitaSpring Biomedical Analyst Ratings and Price Targets | OTC:VSBC | Benzinga

VitaSpring Biomedical Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for VitaSpring Biomedical Corp from these most-recent analyst ratings.

Analyst Ratings for VitaSpring Biomedical

Buy NowGet Alert
No data available to display

FAQ

Q

What is the target price for VitaSpring Biomedical (VSBC) stock?

A

There is no price target for VitaSpring Biomedical

Q

What is the most recent analyst rating for VitaSpring Biomedical (VSBC)?

A

There is no analyst for VitaSpring Biomedical

Q

When was the last upgrade for VitaSpring Biomedical (VSBC)?

A

There is no last upgrade for VitaSpring Biomedical

Q

When was the last downgrade for VitaSpring Biomedical (VSBC)?

A

There is no last downgrade for VitaSpring Biomedical.

Q

When is the next analyst rating going to be posted or updated for VitaSpring Biomedical (VSBC)?

A

There is no next analyst rating for VitaSpring Biomedical.

Q

Is the Analyst Rating VitaSpring Biomedical (VSBC) correct?

A

There is no next analyst rating for VitaSpring Biomedical.

Browse analyst ratings and price targets on all stocks.